Dimerix is increasingly de-risking its commercial path via:
Global licensing strategy (regional commercialization outsourced),
Clinical progress (Phase 3 nearing key milestone),
Non-dilutive funding (upfronts, milestones, R&D rebates).
If Phase 3 data is positive, DXB could unlock significant value. Near term, watch for:
Japan trial site initiation (AU$4.1M milestone)
Ongoing patient dosing completion
Interim data results in Q3
Add to My Watchlist
What is My Watchlist?
